Innovation and industry-academia interactions: Where conflicts arise and measures to avoid them

P. Roy Vagelos, MD
Chairman, Regeneron Pharmaceuticals, Inc.; Chairman, Theravance, Inc.; Former CEO, Merck & Co., Inc.

Correspondence: P. Roy Vagelos, MD, 1 Crossroads Drive, Bedminster, NJ 07921; prv@worldnet.att.net

Dr. Vagelos reported that he has no financial interests, relationships, or affiliations that pose a potential conflict of interest with this article.

P. Roy Vagelos, MD
Chairman, Regeneron Pharmaceuticals, Inc.; Chairman, Theravance, Inc.; Former CEO, Merck & Co., Inc.

Correspondence: P. Roy Vagelos, MD, 1 Crossroads Drive, Bedminster, NJ 07921; prv@worldnet.att.net

Dr. Vagelos reported that he has no financial interests, relationships, or affiliations that pose a potential conflict of interest with this article.

P. Roy Vagelos, MD
Chairman, Regeneron Pharmaceuticals, Inc.; Chairman, Theravance, Inc.; Former CEO, Merck & Co., Inc.

Correspondence: P. Roy Vagelos, MD, 1 Crossroads Drive, Bedminster, NJ 07921; prv@worldnet.att.net

Dr. Vagelos reported that he has no financial interests, relationships, or affiliations that pose a potential conflict of interest with this article.